New hiv drugs

There are many new HIV drugs that have been approved in recent years, offering improved treatment options for people living with HIV. Here are some examples:

  1. Bictegravir (BIC): Approved in 2018, BIC is a new integrase inhibitor that is used in combination with other antiretroviral drugs to treat HIV-1 infection. It has been shown to be highly effective and well-tolerated.
  2. Doravirine (PIFELTRO): Approved in 2019, Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that is used in combination with other antiretroviral drugs to treat HIV-1 infection. It has been shown to be effective and well-tolerated, with a lower risk of side effects compared to other NNRTIs.
  3. Cabotegravir (Cabotegravir): Approved in 2018, Cabotegravir is an integrase inhibitor that is used in combination with other antiretroviral drugs to treat HIV-1 infection. It has been shown to be highly effective and well-tolerated, and is also being studied as a long-acting injectable treatment.
  4. Ibalizumab (Trogarzo): Approved in 2018, Ibalizumab is a monoclonal antibody that is used to treat multidrug-resistant HIV-1 infection. It works by binding to a protein on the surface of HIV-infected cells, preventing the virus from entering the cells.
  5. Fostemsavir (Biktarvy): Approved in 2019, Fostemsavir is a post-attachment inhibitor that is used in combination with other antiretroviral drugs to treat HIV-1 infection. It works by preventing the virus from entering the cells, and has been shown to be effective and well-tolerated.
  6. Lamivudine (Epivir): Approved in 2019, Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that is used in combination with other antiretroviral drugs to treat HIV-1 infection. It has been shown to be effective and well-tolerated, and is also used to treat hepatitis B virus (HBV) infection.
  7. Rilpivirine (Edurant): Approved in 2019, Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that is used in combination with other antiretroviral drugs to treat HIV-1 infection. It has been shown to be effective and well-tolerated, and is also being studied as a long-acting injectable treatment.
  8. Genvoya (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide): Approved in 2015, Genvoya is a fixed-dose combination pill that contains four antiretroviral drugs: elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. It is used to treat HIV-1 infection and has been shown to be effective and well-tolerated.
  9. Descovy (Emtricitabine, Tenofovir alafenamide): Approved in 2016, Descovy is a fixed-dose combination pill that contains two antiretroviral drugs: emtricitabine and tenofovir alafenamide. It is used to treat HIV-1 infection and has been shown to be effective and well-tolerated.
  10. Odefsey (Emtricitabine, Rilpivirine, Tenofovir alafenamide): Approved in 2014, Odefsey is a fixed-dose combination pill that contains three antiretroviral drugs: emtricitabine, rilpivirine, and tenofovir alafenamide. It is used to treat HIV-1 infection and has been shown to be effective and well-tolerated.

These are just a few examples of the many new HIV drugs that have been approved in recent years. It's important to note that each person's treatment plan is unique and should be tailored to their individual needs and circumstances.